Rolando Gutiérrez-Esteinou is the Chief Medical Officer at atai Life Sciences since 1 January 2021. Dr. Gutiérrez-Esteinou has over 25 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Dr. Gutiérrez-Esteinou has held various titles of Chief Medical Officer, SVP or VP in Clinical Development, Project Management, Medical Affairs, and Pharmacovigilance at Novartis, J&J and BMS, and small biotech companies, as well as serving as therapeutic area head in Neuroscience at Covance, a large clinical research organization.

Dr. Gutiérrez-Esteinou is a graduate of the National Autonomous University of Mexico School of Medicine, in Mexico City, and completed a medicine internship and a residency in Adult Psychiatry at Harvard Medical School. He was the recipient of a Fogerty International Fellowship at the National Institute of Mental Health in the Experimental Therapeutics Branch.